Rezolute (RZLT) Cash from Financing Activities (2010 - 2026)
Rezolute (RZLT) posted Cash from Financing Activities of $747000.0 for Q1 2026, up 109.83% sequentially from $356000.0 in Q4 2025, and up 7370.0% YoY from $10000.0 in Q1 2025.
Powered by 
Analysis
Rezolute (RZLT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Rezolute has reported Cash from Financing Activities for 16 years, with the latest figure at $747000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 7370.0% year-over-year to $747000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.2 million (up 48.47% YoY) and the FY2025 annual result came in at $107.3 million, up 70.28% from the prior year.
- Cash from Financing Activities climbed to $747000.0 in Q1 2026 per RZLT's latest filing, from $356000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $101.2 million in Q2 2025 and troughed at -$19000.0 in Q1 2022.
- A 4-year average of $23.2 million and a median of $829000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities sank 83.44% in 2025, then jumped 7370.0% in 2026.
- Over 4 years, Cash from Financing Activities stood at $11.6 million in 2022, then plunged by 94.32% to $657000.0 in 2024, then slumped by 45.81% to $356000.0 in 2025, then soared by 109.83% to $747000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $747000.0, $356000.0, and $911000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | 747,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 747,000.00 |
| Dec 31, 2025 | 356,000.00 |
| Sep 30, 2025 | 911,000.00 |
| Jun 30, 2025 | 101.16 Mn |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 657,000.00 |
| Sep 30, 2024 | 5.50 Mn |
| Jun 30, 2024 | 63.33 Mn |
| Mar 31, 2024 | -3,000.00 |
| Sep 30, 2022 | 11.57 Mn |
| Jun 30, 2022 | 94.10 Mn |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | 52.31 Mn |
| Sep 30, 2021 | 2.59 Mn |
| Jun 30, 2021 | 14.29 Mn |
| Mar 31, 2021 | -214,000.00 |
| Dec 31, 2020 | 37.46 Mn |
| Dec 31, 2019 | -21,000.00 |
| Sep 30, 2019 | 22.57 Mn |
| Mar 31, 2019 | 23.50 Mn |